rademikibart

all catalysts(0)

nothing on the calendar yet

News(2)

• Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal
  Connect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce respiratory attacks—although the study missed a secondary endpoint tied…
  fiercebiotech · 4d ago
• Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
  Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a phase 2 asthma study.
  fiercebiotech · 19d ago